FBLG.US FibroBiologics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
0.9271 USD
Close of Nov 14, 2026
0.6200 9.60
Market cap
USD 6.57M
P/E
-
P/B
1.45x
ROE
-302.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is FBLG.US undervalued?

Graham number

The Graham number of FibroBiologics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

FibroBiologics, Inc. Common Stock fundamental analysis

No fundamental analysis for FibroBiologics, Inc. Common Stock yet.

FibroBiologics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About FibroBiologics, Inc. Common Stock

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatmen…

Full company profile